Almost half of biotech, pharma and medical device managers (47 percent) consider payer pressure and utilization limits to be the biggest impact on their commercial operations, according to a KPMG survey.
"Pressure is coming from every angle against the pharmaceutical industry, requiring a significant, integrated response," said Alison Little, KPMG's advisory life sciences segment leader in the United States. "Life sciences companies face increasingly high demands from payers to prove the value of their products in terms of improved patient outcomes and lower costs."
The survey respondent also listed the following as having an impact on commercial operations:
• Restrictive regulatory environment: 15 percent
• Shift toward specialty medicines: 12 percent
• Requirements for evidence-based medicine: 9 percent
• Value-based care or decreasing access to healthcare providers: 8 percent